ArticleFrontiers in public health2026
Digital therapeutics use burden in patients with chronic diseases: a scoping review.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically map the available evidence on the potential use burden of digital therapeutics (DTx) and DTx-related therapeutic digital interventions in patients with chronic diseases and to inform clinical implementation and policy evaluation. Methods: PubMed, Web of Science (WOS), Cochrane Library, Embase, Wiley, Scopus, CNKI, WanFang Data, VIP, and SinoMed databases were searched from inception to April 28, 2026. Studies were screened according to the inclusion and exclusion criteria. Data were extracted on application areas, potential sources of DTx use burden, indirect burden-related evaluation indicators, and support strategies potentially relevant to reducing DTx use burden. Results: A total of 11 studies were included. DTx and DTx-related therapeutic digital interventions for patients with chronic diseases were mainly applied in diabetes, hypertension, coronary heart disease, chronic insomnia, cancer treatment support, and inflammatory bowel disease. None of the included studies used a dedicated instrument to directly measure DTx use burden. Instead, burden-related evidence was mainly derived from indirect indicators, including utilization and participation indicators, module and task completion indicators, data recording indicators, acceptability and satisfaction indicators, and technical problems and safety records. The task requirements, use difficulties, and indirect indicators reported in the included studies suggested five potential sources of DTx use burden: digital access burden, data recording burden, task completion burden, continuous use burden, and technical operation burden. Conclusion: Evidence on DTx use burden in patients with chronic diseases remains preliminary, and direct measurement of patients' subjective DTx use burden is limited. Future studies should combine patient-reported DTx use burden with objective usage data and documented reasons for discontinuation, and incorporate burden-related outcomes into implementation and policy evaluation to improve accessibility, continuity of use, equity, and implementation sustainability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.